Aobiome

optional text here

Annalisa Jenkins has more than 25 years of industry experience and has worked on building and financing biotech companies pursuing treatments for rare diseases. She has led teams advancing programs from scientific research.

Douglas Rosefsky has nearly 30 years of executive, board, general management and investment experience. He is a founding partner of a small-cap investment fund based in Paris and previously held leadership roles at Alvarez & Marsal.

Jamie entered biomedicine after Jamie’s brother was diagnosed with ALS in 1999, founded or co-founded five companies, and was appointed to the National Biosurveillance Advisory Subcommittee under Presidents Bush and Obama.

Dr. Jun Wang is the founder and CEO of iCarbonX, responsible for the company’s general management and business development and a member of its Board of Directors. In 1999, Dr. Wang co-founded BGI, a research facility focused on genome sciences.

AOBiome Therapeutics, Inc. provides contact details for general inquiries, press inquiries, partnering requests, and career inquiries. Its products were previously sold under the AO+ Mist and Mother Dirt brand names.

AOBiome is a clinical-stage microbiome company developing therapeutics for inflammatory conditions, central nervous system disorders and other diseases. Its product candidates use a strain of ammonia-oxidizing bacteria, or AOB.

The AOBiome.com terms of use state that AOBiome LLC provides the site and that references to “we,” “us,” and “our” include AOBiome and its affiliates.